Skip to main content
. 2021 Dec 2;37(3):513–524. doi: 10.1002/mds.28879

FIG. 2.

FIG. 2

Cognitive outcomes using Cognitive Drug Research‐Continuity of Attention (CDR‐CoA) and Alzheimer's Disease Assessment Scale‐Cognitive Subscale 13 (ADAS‐cog13). CDR‐CoA (A) was the primary endpoint, while ADAS‐cog13 (B) was a key secondary endpoint in the PRESENCE trial. P values between treatment groups were non‐significant and are not shown. N numbers per group are shown below the associated time point. Abbreviations: LS, least squares; N, number of participants.